Effect of Rivaroxaban in Coronary artery disease patients - Observational study

Not Applicable

• Conditions: Health Condition 1: I259- Chronic ischemic heart disease, unspecified

• Registration Number: CTRI/2021/05/033907
• Lead Sponsor: Emcure Pharmaceuticals Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Age >18 years, either gender having a diagnosis of coronary artery disease and meeting the following additional criteria

a. Taking antiplatelet therapy for coronary artery disease or peripheral artery disease

b. Having �2 vascular beds affected or eligible to take an oral anticoagulant therapy

2. Willing to provide written informed consent and for follow up of one year from the date of registration.

Exclusion Criteria

1. Patients having a diagnosis of atrial fibrillation (valvular or non-valvular) prior to or at the time of index acute coronary event or diagnosis.

2. Patients on high doses of newer oral anticoagulants - �10mg per day.

3. Patients on vitamin K antagonist for any reason.

4. Patients not likely to cooperate for data collection and follow up ââ?¬â?? investigatorââ?¬•s decision.

Study & Design

• Study Type: PMS
• Study Design: Not specified